Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Total Current Liabilities (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Total Current Liabilities readings, the most recent being $1.6 million for Q3 2025.

  • Quarterly Total Current Liabilities rose 92.55% to $1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 92.55% year-over-year, with the annual reading at $1.6 million for FY2024, 429.79% up from the prior year.
  • Total Current Liabilities hit $1.6 million in Q3 2025 for Greenwich LifeSciences, down from $1.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.7 million in Q2 2025 and bottomed at $229134.0 in Q2 2022.
  • Average Total Current Liabilities over 5 years is $692463.0, with a median of $389611.0 recorded in 2024.
  • The largest annual shift saw Total Current Liabilities crashed 71.84% in 2021 before it soared 429.79% in 2024.
  • Greenwich LifeSciences' Total Current Liabilities stood at $385172.0 in 2021, then plummeted by 31.74% to $262905.0 in 2022, then grew by 11.98% to $294406.0 in 2023, then soared by 429.79% to $1.6 million in 2024, then rose by 3.99% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Total Current Liabilities are $1.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.4 million (Q1 2025).